

Table 2: Comparative susceptibilities of Gram-positive pathogens to tigecycline and other antibacterial agents in 2005 (G-TEST I) and in 2007 (G-TEST II)

Organism	No. of isolates tested		Antibacterial agent	MIC ($\mu\text{g/mL}$)				% susceptible		% resistant						
	G-TEST I	G-TEST II		50%		90%		G-TEST I	G-TEST II	G-TEST I	G-TEST II					
				G-TEST I	G-TEST II	G-TEST I	G-TEST II									
<i>E. faecalis</i>	150	149	Tigecycline	≤ 0.125	≤ 0.125	≤ 0.125	≤ 0.125	100	100	0	0					
			Doxycycline	8	8	16	16	23.3	19.5	70.7	59.7					
			Amoxicillin-clavulanic acid	0.5	0.5	1	1	100	99.3	0	0.7					
			Piperacillin-tazobactam	2	2	8	8	n.d.	n.d.	n.d.	n.d.					
			Imipenem	1	1	2	2	99.3	99.3	0	0.7					
			Moxifloxacin	0.5	0.5	≥ 16	≥ 16	n.d.	n.d.	n.d.	n.d.					
			Linezolid	2	2	2	2	100	100	0	0					
			Vancomycin	1	1	2	2	100	100	0	0					
Gentamicin (high level) ^a									38.0	38.9						
<i>E. faecium</i>	145	142	Tigecycline	≤ 0.125	≤ 0.125	≤ 0.125	≤ 0.125	100	100	0	0					
			Doxycycline	≤ 0.25	≤ 0.25	8	4	69.0	78.2	11.7	6.3					
			Amoxicillin-clavulanic acid	≥ 32	≥ 32	≥ 32	≥ 32	4.8	7.0	91.7	93.0					
			Piperacillin-tazobactam	≥ 128	≥ 128	≥ 128	≥ 128	n.d.	n.d.	n.d.	n.d.					
			Imipenem	≥ 64	≥ 64	≥ 64	≥ 64	4.8	6.3	95.2	93.0					
			Moxifloxacin	≥ 16	≥ 16	≥ 16	≥ 16	n.d.	n.d.	n.d.	n.d.					
			Linezolid	2	1	2	2	99.3	100	0.7	0					
			Vancomycin	0.5	1	8	≥ 32	89.0	81.7	9.7	18.3					
Gentamicin (high level) ^a									43.4	37.3						
Oxacillin-susceptible <i>S. aureus</i>	148	153	Tigecycline	≤ 0.125	≤ 0.125	≤ 0.125	0.25	100	100	0	0					
			Doxycycline	≤ 0.25	≤ 0.25	≤ 0.25	≤ 0.25	96.6	94.1	3.4	2.6					
			Penicillin G	2	1	≥ 8	≥ 8	20.9	28.8	79.1	71.2					
			Amoxicillin-clavulanic acid	0.5	1	1	1	n.d.	n.d.	n.d.	n.d.					
			Piperacillin-tazobactam	≤ 0.5	≤ 0.5	1	1	n.d.	n.d.	n.d.	n.d.					
			Cefuroxime	2	1	2	2	n.d.	n.d.	n.d.	n.d.					
			Imipenem	≤ 0.25	≤ 0.25	≤ 0.25	0.5	n.d.	n.d.	n.d.	n.d.					
			Moxifloxacin	≤ 0.063	≤ 0.063	4	4	82.4	86.9	13.5	11.8					
			Linezolid	2	2	4	4	100	100	0	0					
			Vancomycin	1	0.5	1	1	100	100	0	0					
Gentamicin									92.6	92.2	7.4	7.8				
Oxacillin-resistant <i>S. aureus</i>	154	155	Tigecycline	≤ 0.125	0.25	0.25	0.25	100	100	0	0					
			Doxycycline	≤ 0.25	≤ 0.25	0.5	≤ 0.25	93.5	96.1	5.8	3.9					
			Penicillin G	≥ 8	≥ 8	≥ 8	≥ 8	n.d.	n.d.	n.d.	n.d.					
			Amoxicillin-clavulanic acid	16	≥ 32	≥ 32	≥ 32	n.d.	n.d.	n.d.	n.d.					
			Piperacillin-tazobactam	64	64	≥ 128	≥ 128	n.d.	n.d.	n.d.	n.d.					
			Cefuroxime	≥ 64	≥ 64	≥ 64	≥ 64	n.d.	n.d.	n.d.	n.d.					
			Imipenem	4	4	≥ 64	32	n.d.	n.d.	n.d.	n.d.					
			Moxifloxacin	4	4	8	8	1.3	1.9	90.9	94.8					
			Linezolid	2	2	4	4	100	100	0	0					
			Vancomycin	1	1	1	1	100	100	0	0					
Gentamicin									1	0.5	≥ 32	16	77.3	87.1	22.7	12.9

Table 2 (continued)

Organism	No. of isolates tested		Antibacterial agent	MIC (µg/mL)				% susceptible		% resistant	
				50%		90%		G-TEST I	G-TEST II	G-TEST I	G-TEST II
	G-TEST I	G-TEST II		G-TEST I	G-TEST II	G-TEST I	G-TEST II				
<i>S. epidermidis</i>	168	142	Oxacillin	≥16	≥16	≥16	≥16	17.3	16.9	82.7	83.1
			Tigecycline	0.25	0.25	0.5	0.5	100	100	0	0
			Doxycycline	0.5	0.5	4	2	86.9	85.9	10.1	9.2
			Penicillin G	≥8	4	≥8	≥8	8.9	12.0	91.1	88.0
			Amoxicillin-clavulanic acid	2	2	8	8	n.d.	n.d.	n.d.	n.d.
			Piperacillin-tazobactam	2	2	16	16	n.d.	n.d.	n.d.	n.d.
			Cefuroxime	8	8	≥64	≥64	n.d.	n.d.	n.d.	n.d.
			Imipenem	1	2	16	16	n.d.	n.d.	n.d.	n.d.
			Moxifloxacin	1	2	2	4	33.9	33.1	42.3	52.1
			Linezolid	1	1	2	2	100	100	0	0
			Vancomycin	2	1	2	2	100	100	0	0
			Gentamicin	16	8	≥32	≥32	34.5	43.7	65.5	56.3
<i>S. haemolyticus</i>	73	66	Oxacillin	≥16	≥16	≥16	≥16	9.6	9.1	90.4	90.9
			Tigecycline	0.25	0.25	0.5	0.5	98.6	95.1	1.4	4.5
			Doxycycline	0.5	0.5	4	8	84.9	86.4	5.5	12.1
			Penicillin G	≥8	≥8	≥8	≥8	4.1	6.1	95.9	93.9
			Amoxicillin-clavulanic acid	16	16	≥32	≥32	n.d.	n.d.	n.d.	n.d.
			Piperacillin-tazobactam	64	16	≥128	≥128	n.d.	n.d.	n.d.	n.d.
			Cefuroxime	≥64	≥64	≥64	≥64	n.d.	n.d.	n.d.	n.d.
			Imipenem	32	8	≥64	≥64	n.d.	n.d.	n.d.	n.d.
			Moxifloxacin	2	2	4	4	19.2	22.7	57.5	51.5
			Linezolid	1	1	2	1	100	100	0	0
			Vancomycin	1	1	2	1	100	100	0	0
			Gentamicin	≥32	16	≥32	≥32	19.2	15.2	80.8	84.8
<i>S. agalactiae</i>	92	76	Tigecycline	≤0.125	≤0.125	≤0.125	≤0.125	100	100	0	0
			Doxycycline	8	8	16	16	25.0	22.4	70.7	77.6
			Penicillin G	0.063	0.063	0.125	0.125	100	100	0	0
			Amoxicillin-clavulanic acid	≤0.125	≤0.125	≤0.125	≤0.125	n.d.	n.d.	n.d.	n.d.
			Piperacillin-tazobactam	≤0.5	≤0.5	≤0.5	≤0.5	n.d.	n.d.	n.d.	n.d.
			Cefuroxime	≤0.25	≤0.25	≤0.25	≤0.25	100	100	0	0
			Imipenem	≤0.25	≤0.25	≤0.25	≤0.25	100	100	0	0
			Moxifloxacin	0.125	0.125	0.25	0.25	100	100	0	0
			Linezolid	1	1	2	2	100	100	0	0
			Vancomycin	0.5	0.5	0.5	0.5	100	100	0	0
			Gentamicin	8	16	16	16	n.d.	n.d.	n.d.	n.d.
			<i>S. pneumoniae</i>	58	70	Tigecycline	≤0.125	≤0.125	≤0.125	≤0.125	n.d.
Doxycycline	≤0.25	≤0.25				0.5	4	91.4	88.6	5.2	11.4
Penicillin G	≤0.031	≤0.031				0.125	0.25	87.9	85.7	0	0
Amoxicillin-clavulanic acid	≤0.125	≤0.125				≤0.125	0.25	n.d.	n.d.	n.d.	n.d.
Piperacillin-tazobactam	≤0.5	≤0.5				≤0.5	≤0.5	n.d.	n.d.	n.d.	n.d.
Cefuroxime	≤0.25	≤0.25				≤0.25	0.5	96.6	91.4	3.4	7.1
Imipenem	≤0.25	≤0.25				≤0.25	0.5	100	100	0	0
Moxifloxacin	0.125	0.125				0.25	0.25	100	100	0	0
Linezolid	1	1				1	1	100	100	0	0
Vancomycin	0.25	0.25				0.5	0.25	100	100	0	0
Gentamicin	4	4				4	8	n.d.	n.d.	n.d.	n.d.
<i>S. pyogenes</i>	54	63				Tigecycline	≤0.125	≤0.125	≤0.125	≤0.125	100
			Doxycycline	≤0.25	≤0.25	8	8	85.2	82.5	13.0	17.5
			Penicillin G	≤0.031	≤0.031	≤0.031	≤0.031	100	100	0	0
			Amoxicillin-clavulanic acid	≤0.125	≤0.125	≤0.125	≤0.125	n.d.	n.d.	n.d.	n.d.
			Piperacillin-tazobactam	≤0.5	≤0.5	≤0.5	≤0.5	n.d.	n.d.	n.d.	n.d.
			Cefuroxime	≤0.25	≤0.25	≤0.25	≤0.25	100	100	0	0
			Imipenem	≤0.25	≤0.25	≤0.25	≤0.25	100	100	0	0
			Moxifloxacin	0.125	0.125	0.25	0.25	100	100	0	0
			Linezolid	1	1	1	1	100	100	0	0
			Vancomycin	0.5	0.5	0.5	0.5	100	100	0	0
			Gentamicin	4	4	4	4	n.d.	n.d.	n.d.	n.d.

n.d.=not determined as no species-related breakpoint has been approved by the EUCAST

[†]MIC >500 mg/l

Table 3: Comparative susceptibilities of Gram-negative pathogens to tigecycline and other antibacterial agents in 2005 (G-TEST I) and in 2007 (G-TEST II)

Organism	No. of isolates tested		Antibacterial agent	MIC ($\mu\text{g/mL}$)				% susceptible		% resistant	
	G-TEST I	G-TEST II		50%		90%		G-TEST I	G-TEST II	G-TEST I	G-TEST II
				G-TEST I	G-TEST II	G-TEST I	G-TEST II				
<i>A. baumannii</i> group	140	117	Tigecycline	0.25	0.25	0.5	1	n.d.	n.d.	n.d.	n.d.
			Doxycycline	≤ 0.25	≤ 0.25	1	4	n.d.	n.d.	n.d.	n.d.
			Amoxicillin-clavulanic acid	16	16	32	≥ 128	n.d.	n.d.	n.d.	n.d.
			Piperacillin-tazobactam	2	2	32	≥ 128	n.d.	n.d.	n.d.	n.d.
			Cefotaxime	8	16	≥ 64	≥ 64	n.d.	n.d.	n.d.	n.d.
			Ceftazidime	4	4	32	≥ 64	n.d.	n.d.	n.d.	n.d.
			Cefepime	4	4	16	≥ 64	n.d.	n.d.	n.d.	n.d.
			Imipenem	≤ 0.25	0.5	0.5	16	97.9	84.6	0.7	11.1
			Ertapenem	4	4	8	≥ 64	n.d.	n.d.	n.d.	n.d.
			Ciprofloxacin	0.25	0.25	≥ 16	≥ 16	70.0	72.6	30.0	27.4
			Moxifloxacin	≤ 0.063	≤ 0.063	4	≥ 16	n.d.	n.d.	n.d.	n.d.
Gentamicin	1	1	16	≥ 32	86.4	77.8	13.6	22.2			
<i>E. cloacae</i>	232	223	Tigecycline	0.5	0.5	2	1	89.7	90.1	6.9	6.3
			Doxycycline	2	2	8	8	30.2	26.0	10.8	10.8
			Amoxicillin-clavulanic acid	≥ 64	≥ 64	≥ 64	≥ 64	0	3.1	98.7	96.4
			Piperacillin-tazobactam	2	2	32	64	72.8	72.6	18.5	22.0
			Cefotaxime	1	0.5	≥ 64	≥ 64	57.8	56.5	40.5	42.6
			Ceftazidime	0.5	0.5	≥ 64	≥ 64	57.3	59.2	29.3	34.1
			Cefepime	≤ 0.25	≤ 0.25	4	4	78.4	78.9	3.4	2.2
			Imipenem	0.5	0.5	1	1	100	100	0	0
			Ertapenem	≤ 0.25	≤ 0.25	1	1	88.4	83.9	3.9	8.5
			Ciprofloxacin	≤ 0.063	≤ 0.063	0.25	0.5	92.7	91.5	5.6	7.2
			Moxifloxacin	≤ 0.063	≤ 0.063	0.5	1	91.4	88.3	6.0	9.4
			Gentamicin	0.5	0.5	1	2	94.0	90.6	4.7	6.3
			<i>E. coli</i>	300	292	Tigecycline	≤ 0.125	≤ 0.125	0.25	0.25	100
Doxycycline	2	1				32	≥ 64	46.3	50.0	44.0	40.4
Amoxicillin-clavulanic acid	8	8				16	16	18.3	16.1	24.3	28.8
Piperacillin-tazobactam	1	1				4	8	94.7	91.8	3.7	6.2
Cefotaxime	≤ 0.25	≤ 0.25				≤ 0.25	≥ 64	94.3	87.7	5.3	12.3
Ceftazidime	≤ 0.25	≤ 0.25				0.5	2	94.0	88.0	2.0	5.8
Cefepime	≤ 0.25	≤ 0.25				0.5	8	94.0	88.0	3.0	9.9
Imipenem	≤ 0.25	0.5				0.5	1	100	100	0	0
Ertapenem	≤ 0.25	≤ 0.25				≤ 0.25	≤ 0.25	100	100	0	0
Ciprofloxacin	≤ 0.063	≤ 0.063				≥ 16	≥ 16	78.0	71.2	21.7	28.4
Moxifloxacin	≤ 0.063	≤ 0.063				≥ 16	≥ 16	77.3	70.2	21.7	28.8
Gentamicin	0.5	1				2	8	91.3	88.7	7.7	10.3
<i>H. influenzae</i>	185	225				Tigecycline	0.25	≤ 0.125	0.25	0.5	n.d.
			Doxycycline	≤ 0.25	≤ 0.25	0.5	0.5	98.9	98.7	0	0.9
			Amoxicillin-clavulanic acid	≤ 0.25	≤ 0.25	1	1	96.8	94.7	3.2	5.3
			Piperacillin-tazobactam	≤ 0.5	≤ 0.5	≤ 0.5	≤ 0.5	n.d.	n.d.	n.d.	n.d.
			Cefotaxime	≤ 0.25	≤ 0.25	≤ 0.25	≤ 0.25	^a	^a	^a	^a
			Ceftazidime	≤ 0.25	≤ 0.25	≤ 0.25	≤ 0.25	n.d.	n.d.	n.d.	n.d.
			Cefepime	≤ 0.25	≤ 0.25	≤ 0.25	≤ 0.25	99.5	99.1	0.5	0.9
			Imipenem	0.5	0.5	1	1	100	98.2	0	1.8
			Ertapenem	≤ 0.25	≤ 0.25	≤ 0.25	≤ 0.25	100	100	0	0
			Ciprofloxacin	≤ 0.063	≤ 0.063	≤ 0.063	≤ 0.063	100	100	0	0
			Moxifloxacin	≤ 0.063	≤ 0.063	≤ 0.063	≤ 0.063	100	100	0	0
			Gentamicin	2	2	2	2	n.d.	n.d.	n.d.	n.d.

Table 3 (continued)

Organism	No. of isolates tested		Antibacterial agent	MIC (µg/mL)				% susceptible		% resistant	
	G-TEST I	G-TEST II		50%		90%		G-TEST I	G-TEST II	G-TEST I	G-TEST II
				G-TEST I	G-TEST II	G-TEST I	G-TEST II				
<i>K. oxytoca</i>	100	109	Tigecycline	0.25	0.25	0.5	1	97.0	93.6	2.0	1.8
			Doxycycline	0.5	1	4	8	84.0	66.1	4.0	16.5
			Amoxicillin-clavulanic acid	2	4	16	32	69.0	39.4	15.0	25.7
			Piperacillin-tazobactam	1	2	≥128	≥128	85.0	74.3	14.0	23.9
			Cefotaxime	≤0.25	≤0.25	1	4	92.0	79.8	3.0	15.6
			Ceftazidime	≤0.25	≤0.25	0.5	2	94.0	86.2	0	0.9
			Cefepime	≤0.25	≤0.25	1	8	93.0	78.9	0	2.8
			Imipenem	≤0.25	0.5	0.5	1	100	100	0	0
			Ertapenem	≤0.25	≤0.25	≤0.25	≤0.25	100	100	0	0
			Ciprofloxacin	≤0.063	≤0.063	0.125	4	93.0	82.6	6.0	13.8
			Moxifloxacin	0.125	0.125	0.25	4	92.0	79.8	7.0	16.5
			Gentamicin	0.5	1	1	2	99.0	94.5	1.0	4.6
			<i>K. pneumoniae</i>	186	185	Tigecycline	0.5	0.5	4	2	82.3
Doxycycline	1	2				16	16	55.9	40.0	26.9	26.5
Amoxicillin-clavulanic acid	2	4				16	32	58.1	49.2	13.4	19.5
Piperacillin-tazobactam	2	2				8	32	91.4	84.3	8.1	10.3
Cefotaxime	≤0.25	≤0.25				0.5	16	93.0	85.9	5.4	13.5
Ceftazidime	≤0.25	≤0.25				1	16	92.5	84.9	4.3	10.3
Cefepime	≤0.25	≤0.25				1	4	91.4	84.3	4.8	7.6
Imipenem	≤0.25	0.5				0.5	1	98.9	100	0	0
Ertapenem	≤0.25	≤0.25				≤0.25	≤0.25	97.8	97.8	1.1	0.5
Ciprofloxacin	≤0.063	≤0.063				0.5	≥16	90.3	82.2	8.1	16.8
Moxifloxacin	0.125	0.125				1	8	87.1	74.1	7.0	20.0
Gentamicin	0.5	0.5				1	1	96.8	94.6	3.2	5.4
<i>S. marcescens</i>	118	124				Tigecycline	1	1	2	2	80.5
			Doxycycline	4	4	16	16	0.8	0	41.5	42.7
			Amoxicillin-clavulanic acid	≥64	≥64	≥64	≥64	1.7	0.8	92.4	98.4
			Piperacillin-tazobactam	1	2	4	32	95.8	87.1	2.5	9.7
			Cefotaxime	≤0.25	0.5	2	16	89.0	79.0	6.8	17.7
			Ceftazidime	≤0.25	≤0.25	1	1	91.5	91.1	1.7	1.6
			Cefepime	≤0.25	≤0.25	0.5	1	94.1	95.2	2.5	0
			Imipenem	0.5	1	1	1	100	100	0	0
			Ertapenem	≤0.25	≤0.25	0.5	0.5	93.2	91.9	4.2	2.4
			Ciprofloxacin	≤0.063	≤0.063	0.5	2	92.4	83.1	5.9	12.9
			Moxifloxacin	0.25	0.25	1	4	86.4	74.2	8.5	17.7
			Gentamicin	0.5	1	1	2	94.9	95.2	2.5	2.4
			<i>S. maltophilia</i>	157	129	Tigecycline	0.5	0.5	2	1	n.d.
Doxycycline	2	2				4	4	n.d.	n.d.	n.d.	n.d.
Amoxicillin-clavulanic acid	≥64	≥64				≥64	≥64	n.d.	n.d.	n.d.	n.d.
Piperacillin-tazobactam	≥128	≥128				≥128	≥128	n.d.	n.d.	n.d.	n.d.
Cefotaxime	≥64	≥64				≥64	≥64	n.d.	n.d.	n.d.	n.d.
Ceftazidime	≥64	≥64				≥64	≥64	n.d.	n.d.	n.d.	n.d.
Cefepime	≥64	≥64				≥64	≥64	n.d.	n.d.	n.d.	n.d.
Imipenem	≥64	≥64				≥64	≥64	n.d.	n.d.	n.d.	n.d.
Ertapenem	≥64	≥64				≥64	≥64	n.d.	n.d.	n.d.	n.d.
Ciprofloxacin	2	2				≥16	8	n.d.	n.d.	n.d.	n.d.
Moxifloxacin	0.5	0.5				2	2	n.d.	n.d.	n.d.	n.d.
Gentamicin	≥32	≥32				≥32	≥32	n.d.	n.d.	n.d.	n.d.

n.d.=not determined as no species-related breakpoint has been approved by the EUCAST

^aThe percentage could not be determined as the breakpoint is below the lowest concentration tested.